Anti-SPARC oligopeptide inhibits laser-induced CNV in mice

Vision Res. 2010 Mar 31;50(7):674-9. doi: 10.1016/j.visres.2009.12.003. Epub 2009 Dec 22.

Abstract

It is known that SPARC gates VEGF-A signal transduction towards KDR, the primary angiogenic VEGF receptor. We sought to determine whether inhibition of SPARC activity using anti-SPARC peptide could inhibit laser-induced CNV by promoting binding of VEGF-A to FLT-1. We created anti-SPARC l-peptide and retro-inverso anti-SPARC d-peptide. Anti-SPARC peptides or PBS were injected intravitreally 1day before or after laser induction. Intravitreal injection of anti-SPARC l-peptide 1day before laser induction promotes FLT-1 phosphorylation and inhibited laser-induced CNV and anti-SPARC d-peptide had no effect. Injection 1day after laser injury did not affect size of laser-induced CNV. Inhibition of SPARC activity could be complementary to existing anti-CNV therapy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Choroidal Neovascularization / metabolism*
  • Choroidal Neovascularization / pathology
  • Disease Models, Animal
  • Intravitreal Injections
  • Lasers / adverse effects
  • Mice
  • Mice, Inbred BALB C
  • Oligopeptides / metabolism*
  • Osteonectin / administration & dosage
  • Osteonectin / antagonists & inhibitors*
  • Phosphorylation
  • Vascular Endothelial Growth Factors / metabolism

Substances

  • Oligopeptides
  • Osteonectin
  • Vascular Endothelial Growth Factors